CYP3A4 HUMANIZED MOUSE; A MODEL TO STUDY CYP3A4-MEDIATED DRUG-DRUG INTERACTION POTENTIAL

被引：0
|
作者：
Rose, Anne [1 ]
Xu, Carrie [1 ]
Johnghar, Susan [1 ]
Behnia, Kamelia [1 ]
机构：
[1] Bristol Myers Squibb Co, New York, NY 10154 USA
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：76 / 77
页数：2
相关论文
共 50 条
  • [41] A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates
    Arora, Sumit
    Pansari, Amita
    Kilford, Peter J.
    Jamei, Masoud
    Turner, David B.
    Gardner, Iain
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (04) : 483 - 495
  • [42] Structure-Property Relationships and Machine Learning Models for Addressing CYP3A4-Mediated Victim Drug-Drug Interaction Risk in Drug Discovery
    Hu, Bingjie
    Zhou, Xin
    Mohutsky, Michael A.
    Desai, Prashant, V
    MOLECULAR PHARMACEUTICS, 2020, 17 (09) : 3600 - 3608
  • [43] EVALUATION OF CYP3A4-MEDIATED AND TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) POTENTIAL FOR PEMIGATINIB USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
    Ji, T.
    Zhang, Y.
    Overholt, H.
    Chen, X.
    Yeleswaram, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S68 - S69
  • [44] A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
    Juif, Pierre-Eric
    Boehler, Margaux
    Donazzolo, Yves
    Bruderer, Shirin
    Dingemanse, Jasper
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (09) : 1121 - 1128
  • [45] Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin
    Dutreix, Catherine
    Lorenzo, Sebastien
    Wang, Yanfeng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (08) : 915 - 920
  • [46] A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro (vol 36, pg 1698, 2008)
    不详
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (09) : 1975 - 1975
  • [47] The impact of CYP3A4 genetic polymorphism on crizotinib metabolism and drug-drug interactions
    Wang, Jing
    Xu, Xiao-yu
    Li, Xin-yue
    Luo, Jian-chao
    Zhang, Zhe-yan
    Chen, Jing
    Cai, Jian-ping
    Zhang, Li-kang
    Qian, Jian-chang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 489
  • [48] In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions
    Masamrekh, Rami A.
    Kuzikov, Alexey V.
    Haurychenka, Yaraslau I.
    Shcherbakov, Kirill A.
    Veselovsky, Alexander V.
    Filimonov, Dmitrii A.
    Dmitriev, Alexander V.
    Zavialova, Maria G.
    Gilep, Andrei A.
    Shkel, Tatsiana V.
    Strushkevich, Natallia V.
    Usanov, Sergey A.
    Archakov, Alexander I.
    Shumyantseva, Victoria V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (01) : 120 - 130
  • [49] Comparison of CYP3A4 and CYP3A5 in Drug Metabolism and Drug Interactions
    Li, Shuanmei
    Liu, Duan
    Zhu, Juanli
    Cui, Yan
    Zhou, Ruimin
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32
  • [50] Predicting the Drug–Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation
    Hong-can Ren
    Yang Sai
    Tao Chen
    Chun Zhang
    Lily Tang
    Cheng-guang Yang
    The AAPS Journal, 24
12345